Publication of a Prospectus

RNS Number : 6730N
AstraZeneca PLC
10 August 2017
 

 

10 August 2017 13:30 BST

Publication of Prospectus

Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:

Base Prospectus for the AstraZeneca PLC U.S. $5,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

 

The last drawdown under the EMTN programme was in 2016.

 

To view the full document, please paste the following URL into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/6730N_-2017-8-10.pdf

 

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

 

http://www.morningstar.co.uk/uk/NSM

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations



Esra Erkal-Paler

UK/Global

+44 203 749 5638

Rob Skelding

UK/Global

+44 203 749 5821

Karen Birmingham

UK/Global

+44 203 749 5634

Matt Kent

UK/Global

+44 203 749 5906

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen

 

 

+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology

+1 240 477 3771

Christer Gruvris

Diabetes; Autoimmunity, Neuroscience & Infection

+44 203 749 5711

Nick Stone

Respiratory; Brilinta

+44 203 749 5716

US toll free


+1 866 381 7277


Adrian Kemp

Company Secretary

AstraZeneca PLC


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PDIOKKDNDBKDOFD

Companies

AstraZeneca (AZN)
Investor Meets Company
UK 100

Latest directors dealings